This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient…mehr
This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients.
This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies. Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Carlos Cervera, MD, PhD Division of Infectious Diseases, Department of Medicine. University of Alberta. 1-124F Clinical Sciences Building. 11350 83 Ave. Edmonton T6G 2G3 Alberta, Canada Primary email address: cerveraa@ualberta.ca Jose Maria Aguado, MD, PhD Unit of Infectious Diseases, Research Institute Hospital "12 de Octubre" (i + 12), University Hospital "12 de Octubre", Complutense University of Madrid Madrid, Spain Primary email address: jaguadog1@gmail.com
Inhaltsangabe
Overview on the risk of infection associated with biologic and targeted therapies.- Timeline of infections associated with biologic and targeted therapies.- Infectious disease evaluation of candidates to new therapies.- Vaccines and biologic and targeted therapies.- Travel and risk of infections.- Anti-necrosis tumoral factor-alpha agents.- CD19-targeted agents.- CD20-targeted agents.- CD22-targeted agents.- CD30-targeted agents.- CD33 and CD38-targeted agents.- CD40 and CD319-targeted agents.- CD52-targeted agents.- CCR4-targeted agents.- Cell-surface receptors I: VEFG targeted agents.- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents.- Interleukin-1 targeted agents.- Interleukin-5 and interleukin-6 targeted agents.- Interleukin-12/23 p40 targeted agents.- Sphingosine-1 phosphate receptor modulators.- Immune checkpoint inhibitors.- 4-integrin-targeted agents.- Tyrosin-kinase inhibitors.- Bcl-2, JAK and mTOR inhibitors.- Infections associated with the use ofCarT cells.- Pulmonary infiltrates.- Tuberculosis.- Cytomegalovirus and other herpesviruses.- Invasive fungal infections.- Progressive multifocal leukoencephalopathy.- Hepatitis virus.
Overview on the risk of infection associated with biologic and targeted therapies.- Timeline of infections associated with biologic and targeted therapies.- Infectious disease evaluation of candidates to new therapies.- Vaccines and biologic and targeted therapies.- Travel and risk of infections.- Anti-necrosis tumoral factor-alpha agents.- CD19-targeted agents.- CD20-targeted agents.- CD22-targeted agents.- CD30-targeted agents.- CD33 and CD38-targeted agents.- CD40 and CD319-targeted agents.- CD52-targeted agents.- CCR4-targeted agents.- Cell-surface receptors I: VEFG targeted agents.- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents.- Interleukin-1 targeted agents.- Interleukin-5 and interleukin-6 targeted agents.- Interleukin-12/23 p40 targeted agents.- Sphingosine-1 phosphate receptor modulators.- Immune checkpoint inhibitors.- α4-integrin-targeted agents.- Tyrosin-kinase inhibitors.- Bcl-2, JAK and mTOR inhibitors.- Infections associated with the use ofCarT cells.- Pulmonary infiltrates.- Tuberculosis.- Cytomegalovirus and other herpesviruses.- Invasive fungal infections.- Progressive multifocal leukoencephalopathy.- Hepatitis virus.
